Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sarepta Therapeutics stock | 139.7

Own Sarepta Therapeutics stock in just a few minutes.

Posted

Fact checked

Sarepta Therapeutics, Inc is a biotechnology business based in the US. Sarepta Therapeutics shares (SRPT) are listed on the NASDAQ and all prices are listed in US Dollars. Sarepta Therapeutics employs 743 staff and has a trailing 12-month revenue of around USD$495.1 million.

How to buy shares in Sarepta Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Sarepta Therapeutics. Find the stock by name or ticker symbol: SRPT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sarepta Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$139.7, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sarepta Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Sarepta Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Sarepta Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Sarepta Therapeutics's share price has had significant positive movement.

Its last market close was USD$139.7, which is 11.25% up on its pre-crash value of USD$123.98 and 78.96% up on the lowest point reached during the March crash when the shares fell as low as USD$78.06.

If you had bought USD$1,000 worth of Sarepta Therapeutics shares at the start of February 2020, those shares would have been worth USD$774.92 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,211.20.

Sarepta Therapeutics share price

Use our graph to track the performance of SRPT stocks over time.

Sarepta Therapeutics shares at a glance

Information last updated 2020-11-25.
Latest market close USD$139.7
52-week range USD$78.06 - USD$175
50-day moving average USD$138.87
200-day moving average USD$148.6644
Wall St. target price USD$189.68
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-8.135

Buy Sarepta Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sarepta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sarepta Therapeutics price performance over time

Historical closes compared with the close of $139.7 from 2020-11-16

1 week (2020-11-15) N/A
1 month (2020-10-26) 0.78%
3 months (2020-08-22) N/A
6 months (2020-05-22) N/A
1 year (2019-11-22) N/A
2 years (2018-11-22) N/A
3 years (2017-11-22) N/A
5 years (2015-11-22) N/A

Is Sarepta Therapeutics under- or over-valued?

Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sarepta Therapeutics's PEG ratio

Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sarepta Therapeutics financials

Revenue TTM USD$495.1 million
Gross profit TTM USD$-236,462,000
Return on assets TTM -17.11%
Return on equity TTM -63.64%
Profit margin -121.3%
Book value $11.322
Market capitalisation USD$10.6 billion

TTM: trailing 12 months

Shorting Sarepta Therapeutics shares

There are currently 8.8 million Sarepta Therapeutics shares held short by investors – that's known as Sarepta Therapeutics's "short interest". This figure is 0.6% down from 8.9 million last month.

There are a few different ways that this level of interest in shorting Sarepta Therapeutics shares can be evaluated.

Sarepta Therapeutics's "short interest ratio" (SIR)

Sarepta Therapeutics's "short interest ratio" (SIR) is the quantity of Sarepta Therapeutics shares currently shorted divided by the average quantity of Sarepta Therapeutics shares traded daily (recently around 810242.73897059). Sarepta Therapeutics's SIR currently stands at 10.88. In other words for every 100,000 Sarepta Therapeutics shares traded daily on the market, roughly 10880 shares are currently held short.

However Sarepta Therapeutics's short interest can also be evaluated against the total number of Sarepta Therapeutics shares, or, against the total number of tradable Sarepta Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sarepta Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Sarepta Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.124% of the tradable shares (for every 100,000 tradable Sarepta Therapeutics shares, roughly 124 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sarepta Therapeutics.

Find out more about how you can short Sarepta Therapeutics stock.

Sarepta Therapeutics share dividends

We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months.

Have Sarepta Therapeutics's shares ever split?

Sarepta Therapeutics's shares were split on a 1:6 basis on 12 July 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Sarepta Therapeutics shares which in turn could have impacted Sarepta Therapeutics's share price.

Sarepta Therapeutics share price volatility

Over the last 12 months, Sarepta Therapeutics's shares have ranged in value from as little as $78.06 up to $175. A popular way to gauge a stock's volatility is its "beta".

SRPT.US volatility(beta: 2.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 2.168. This would suggest that Sarepta Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sarepta Therapeutics overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site